Retrophin Plummets Before All-Day Rally on Early Drug Results
Insights - Retrophin (RTRX) dropped on Friday before rallying through the day on early results for RE-024. Here's why.
Read NowzFree
Flamel Adds Another ‘Approved Unapproved’ Product To its Portfolio
Insights - Flamel Technologies (FLML) announced on Monday that the FDA has approved VAZCULEP (phenylephrine hydrochloride), the company’s alpha-1 adrenergic receptor agonist for the treatment of hypotension resulting … Continue Reading
Read Now
Inhaled Insulin, Breakthrough in Cystic Fibrosis and so Much More
Recap - The announcement came two weeks ahead of schedule, and Afrezza is now approved to improve glycemic control in adults with diabetes mellitus. Afrezza’s label includes a Black Box Warning … Continue Reading
Read Now
Auxilium and QLT Inc: Astute Investors Saw the Exit Coming
Insights - Driven by Canada’s lower corporate tax rate, Auxilium Pharmaceuticals (AUXL) plans to merge with QLT Inc. (QLTI), a small Canadian biotechnology company that essentially put … Continue Reading
Read Now
Vertex: The Biggest Biotech Event of 2014 Goes the Right Way
Insights - Shares of Vertex Pharmaceuticals (VRTX) are up 50% to $100 following success in two phase 3 studies of a cystic fibrosis drug combination that could be worth north … Continue Reading
Read Now
Ohr Calls Drug Analysis ‘Positive’ but Misses Primary Goal
Insights - Ohr Pharmaceutical (OHRP) on Tuesday released interim results from a phase 2 study of its Squalamine eye drops in Wet Age-related Macular Degeneration (AMD). Squalamine eye drops, … Continue Reading
Read Now
Investors Should Celebrate as Shire Goes Up Against AbbVie
Insights - The rejected bid is forcing Shire (SHPG) execs to issue longterm guidance, an uncommon practice in bio, and similar to what's going on at Allergan (AGN)
Read Now